Company InformationThird Pole was founded on January 2014. The company is based in San Francisco, CA, USA . The number of employees in Third Pole is less than 10. Third pole, inc. develops products that generate and deliver electric nitric oxide for hospital, ambulatory, and home use.
Funding & investorsThird Pole has received 2 rounds of venture funding. The total funding amount is around $5.7M.
- Saturn Partners (Micro vc)
Similar Companies [beta]
Active Venture Investors
Third Pole - Blog
- 200 Years of Patient Care. Patient Pioneer: The Story of Courtney Joyce
- Third Pole Therapeutics Secures $15 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.
- Third Pole Therapeutics Expands Board of Directors
- Can Nitric Oxide Prevent COVID-19 Infection or Progression?
- How a discovery that brought us Viagra could help those battling the coronavirus
- How the gas that gave the world Viagra could help treat coronavirus patients
Last week the hospital marked a significant milestone – the 175th anniversary of the first public demonstration of ether in surgery, considered one of most game-changing events in medical history. In the spirit of that Oct. 16, 1846 landmark, the MGH, fittingly, shares the story of Courtney Joyce, who was the first patient at the hospital to benefit from inhaled ... Read More
Waltham, MA – April 15, 2021 – Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today that it has entered into a $15 million debt facility with Avenue Venture Opportunities Fund, L.P. (“Avenue Venture Fund”). Read More >>
Waltham, MA – February 24, 2021 – Third Pole, Inc., a privately held company developing and delivering critical life-sustaining cardio-pulmonary therapies, announced today that it has added two seasoned pharmaceutical executives to its Board of Directors, William Heiden, former CEO and Director of AMAG Pharmaceuticals, and Werner Cautreels, Ph.D., former CEO of Selecta Biosciences. Read More >>
The severity of COVID-19 respiratory failure in some patients has taken the medical community by surprise. And in response, that community has been trying just about anything that seems reasonable in an effort to improve outcomes — and in some cases as last-resort measures to save lives.
Nitric oxide may not be done yet. The colorless, odorless gas, inhaled through a mask or even from a small “flute,” is now being tested as an experimental treatment for COVID-19. It may also prove helpful in protecting healthcare workers on the front line of the pandemic from getting sick.
Medical researchers are testing whether inhaled nitric oxide could help treat patients with the coronavirus.